1. 100 INTERNATIONAL, RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF CC-486 (ORAL AZACITIDINE) IN PATIENTS WITH IPSS INTERMEDIATE-1 MYELODYSPLASTIC SYNDROMES WITH RBC-TRANSFUSION-DEPENDENT ANEMIA AND THROMBOCYTOPENIA: THE QUAZAR LOWER-RISK MDS TRIAL. Issue 1 (April 2015) Authors: Garcia-Manero, G.; Platzbecker, U.; Santini, V.; Voso, M.T.; Garcia, R.; Valcarcel, D.; Silverman, L.R.; Almeida, A.; Giagounidis, A.; Larsen, S.R.; Kreitz, S.; Hoenekopp, A.; Skikne, B.S. Journal: Leukemia research Issue: Volume 39:Issue 1(2015:Jan.) Page Start: S51 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 111 MUTATIONAL PROFILE AND KARYOTYPIC ABNORMALITIES OF CLINICAL TRIAL PATIENTS WITH HIGHER-RISK MDS FOLLOWING FAILURE OF HYPOMETHYLATING AGENTS (HMAS): IMPACT ON RESPONSE TO RIGOSERTIB THERAPY. (April 2015) Authors: Mufti, G.J.; Best, S.; Lea, N.; Hellstrom-Lindberg, E.; Silverman, L.R.; Garcia-Manero, G.; Azarnia, N.; Petrone, M.E.; Snyder, B.R.; Gohring, G. Journal: Leukemia research Issue: Volume 39(2015:Apr.) Supplement 1 Page Start: S57 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 112 RANDOMIZED PHASE III STUDY OF IV RIGOSERTIB VERSUS BEST SUPPORTIVE CARE (BSC) IN PATIENTS WITH HIGHER-RISK MDS (HR-MDS) AFTER FAILURE OF HYPOMETHYLATING AGENTS (HMAS). (April 2015) Authors: Garcia-Manero, G.; Fenaux, P.; Al-Kali, A.; Baer, M.R.; Sekeres, M.; Roboz, G.; Gaidano, G.; Scott, B.; Greenberg, P.; Platzbecker, U.; Steensma, D.P.; Kambhampati, S.; Kreuzer, K.A.; Godley, L.; Collins, R.; Atallah, E.; Azarnia, N.; Petrone, M.E.; Snyder, B.R.; Maniar, M. Journal: Leukemia research Issue: Volume 39(2015:Apr.) Supplement 1 Page Start: S57 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 238 INCIDENCE AND TREATMENT OF PATIENTS WITH MYELODYSPLASTIC SYNDROME (MDS) IN THE US: OPTIMIZATION OR DISAPPOINTING CARE?. Issue 1 (April 2015) Authors: Demakos, E.P.; Silverman, L.R.; Lawrence, M.E.; McKearn, T.J.; Megaffin, S.; Petrone, M.E. Journal: Leukemia research Issue: Volume 39:Issue 1(2015:Jan.) Page Start: S118 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 239 PATTERNS OF CARE FOR HYPOMETHYLATING AGENTS (HMAS) IN MDS PATIENTS IN THE US: A DISTURBING LACK OF OPTIMAL TREATMENT TRANSLATES TO A RECIPE FOR FAILURE. Issue 1 (April 2015) Authors: Demakos, E.P.; Silverman, L.R.; Lawrence, M.E.; McKearn, T.J.; Megaffin, S.; Petrone, M.E. Journal: Leukemia research Issue: Volume 39:Issue 1(2015:Jan.) Page Start: S119 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. 57 A PHASE 2 MULTICENTER STUDY OF CC-486 (ORAL AZACITIDINE) IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS) WHO FAIL TO ACHIEVE RESPONSE WITH INJECTABLE AZACITIDINE OR DECITABINE. (April 2015) Authors: Garcia-Manero, G.; Silverman, L.R.; Komrokji, R.S.; Mufti, G.J.; Seymour, J.F.; Tsai, K.; Reiser, D.; Skikne, B.S.; Beach, C.L.; Fenaux, P. Journal: Leukemia research Issue: Volume 39(2015:Apr.) Supplement 1 Page Start: S28 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. 88 BONE MARROW BLAST (BMBL) RESPONSE CORRELATES WITH OVERALL SURVIVAL IN RIGOSERTIB-TREATED PATIENTS WITH HIGHER-RISK MDS AFTER FAILURE OF HYPOMETHYLATING AGENTS (HMAS): A NEW RESPONSE CRITERION?. (April 2015) Authors: Silverman, L.R.; Fenaux, P.; Al-Kali, A.; Baer, M.R.; Sekeres, M.; Roboz, G.; Gaidano, G.; Scott, B.; Greenberg, P.; Platzbecker, U.; Steensma, D.P.; Kambhampati, S.; Kreuzer, K.A.; Godley, L.; Collins, R.; Atallah, E.; Navada, S.C.; Azarnia, N.; Garcia-Manero, G. Journal: Leukemia research Issue: Volume 39(2015:Apr.) Supplement 1 Page Start: S44 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. 89 A PHASE I STUDY OF THE COMBINATION OF AZACITIDINE AND ORAL RIGOSERTIB IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS) OR ACUTE MYELOID LEUKEMIA (AML). Issue 1 (April 2015) Authors: Navada, S.C.; Garcia-Manero, G.; Hearn, K.; Odchimar-Reissig, R.; Demakos, E.; Alvarado, Y.; Daver, N.; DiNardo, C.; Konopleva, M.; Borthakur, G.; Azarnia, N.; Silverman, L.R. Journal: Leukemia research Issue: Volume 39:Issue 1(2015:Jan.) Page Start: S45 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Rigosertib in Combination with Azacitidine Modulates Epigenetic Pathways and can Overcome Clinical Resistance to Hypomethylating Agents in Myelodysplastic Syndromes (MDS). (April 2017) Authors: Chaurasia, P.; Isoda, F.; Navada, S.; Odchimar-Reissig, R.; Demakos, E.P.; Reddy, E.P.; Silverman, L.R. Journal: Leukemia research Issue: Volume 55(2017)Supplement 1 Page Start: S121 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗